Subjects meeting any of the following criteria cannot be enrolled into the trial: Healthy participants 1. Presence of diseases or therapies that are likely to interfere with the immune response to vaccination. 2. Presence of a disease requiring change in therapy during 4 weeks before enrollment. 3. Any contraindications to the vaccine planned to receive as listed in the product characteristics. 4. Lack of willingness to undergo serial blood draws and attend follow-up appointments. 5. Women who are pregnant or breastfeeding. 6. Previous vaccination with any coronavirus vaccine. 7. Persons who are not willing to sign the informed consents (biobank informed consent and study specific informed consent). Immunodeficient participants 1. Patients with hematological diseases within three months from B-cell-depleting immunotherapy (rituximab, ofatumumab, obinutuzumab, blinatumomab, CAR-T cells). 2. Patients with hematological malignancies in remission and >12 months after end of specific therapy. 3. Patients within three months from HSCT. 4. Any contraindications to the vaccine planned to receive as listed in the product characteristics. 5. Lack of willingness to undergo serial blood draws and attend follow-up appointments. 6. Women who are pregnant or breastfeeding. 7. Previous vaccination with any coronavirus vaccine (exception: if serum prior to vaccination is available from the biobank). 8. Patients who are not willing to sign the informed consents (biobank informed consent and study specific informed consent).

Subjects meeting any of the following criteria cannot be enrolled into the trial: Healthy participants 1. Presence of diseases or therapies that are likely to interfere with the immune response to vaccination. 2. Presence of a disease requiring change in therapy during 4 weeks before enrollment. 3. Any contraindications to the vaccine planned to receive as listed in the product characteristics. 4. Lack of willingness to undergo serial blood draws and attend follow-up appointments. 5. Women who are pregnant or breastfeeding. 6. Previous vaccination with any coronavirus vaccine. 7. Persons who are not willing to sign the informed consents (biobank informed consent and study specific informed consent). Immunodeficient participants 1. Patients with hematological diseases within three months from B-cell-depleting immunotherapy (rituximab, ofatumumab, obinutuzumab, blinatumomab, CAR-T cells). 2. Patients with hematological malignancies in remission and >12 months after end of specific therapy. 3. Patients within three months from HSCT. 4. Any contraindications to the vaccine planned to receive as listed in the product characteristics. 5. Lack of willingness to undergo serial blood draws and attend follow-up appointments. 6. Women who are pregnant or breastfeeding. 7. Previous vaccination with any coronavirus vaccine (exception: if serum prior to vaccination is available from the biobank). 8. Patients who are not willing to sign the informed consents (biobank informed consent and study specific informed consent).